Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18007258 | 1.00 | HSD17B10 (0.36) | HSD17B10SMN1; SMN2LMNACYP2C19RAB9A | |
| SCHEMBL344781 | 0.91 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL18393475 | 0.91 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL344780 | 0.91 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL1786234 | 0.91 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL1791330 | 0.91 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL2881728 | 0.81 | POLB (0.30) | — | |
| SCHEMBL2936194 | 0.81 | — | — | |
| SCHEMBL19468591 | 0.81 | — | — | |
| SCHEMBL3658975 | 0.80 | DPP4 (0.35) | HSD17B10SMN1; SMN2RAB9ADPP4PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016170545-A1 | PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| WO-2016170545-A1 | PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016132383-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | MYLAN LABORATORIES LIMITED (IN) | 2016-08-25 | — | — | WO | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | HSD17B10 4195/4885SMN1; SMN2 4787/4885LMNA 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.